NeuroPASS

Brussels, Belgium, September 9, 2026 UCB announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy...

Baltimore, Maryland, September 9, 2026 CraniUS Therapeutics has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the...

BALTIMORE, June 29, 2026 CraniUS Therapeutics has received an initial $1.1 million award through the National Institutes of Health...